Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Asthma, Obesity

In brief

Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics. Researchers believe this occurs because excess adipose tissue (fat) in the bosy can cause higher-than-normal levels of leptin and lower levels of adiponectin in the blood. The researchers of this study are testing a medication called pioglitazone in overweight asthmatics because they believe it can help regulate leptin and adiponectin and that this may improve symptoms of asthma.

Key facts

Study ID

NCT00787644

Run by

University of Vermont

People needed

28

Starts

2009-01-01

Expected to finish

2013-12-01

Last updated by the study team

2015-02-26

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Asthma diagnosed by a physician at least 1 year prior to study enrollment
• Poorly-controlled asthma at study enrollment
• Non smokers (stopped smoking at least 1 year ago) and limited lifetime history of smoking
• Body mass index 30-60
• Responds to methacholine challenge test with PC20 of <16 mg/ml
• On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry
• FEV1 > 60% predicted
• Able to obtain weekly weights at home

You may not qualify if…

• Systemic steroids within the past 4 weeks
• Lung pathology other than asthma
• Other significant non-pulmonary co-morbidities such as: coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure with an ejection fraction <50%, liver disease or elevated liver enzymes at baseline, malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum creatinine >3.0, or disorders requiring steroid treatment such as vasculitis, lupus, rheumatoid arthritis
• B-type natriuretic peptide (BNP) >400pg/ml
• Pregnant or lactating
• Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or rifampin, a TZD (thiazolidinedione), or allergic to TZD
• Taking antioxidants (if taking a multivitamin must be on a stable regimen prior to enrollment)
• Illicit drug use within the past year
• Current/active upper respiratory infection (if active URI, wait until asymptomatic for 1 week to enroll)
• Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital visits due to asthma resulting in an increase in asthma-related medications)
• Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea (patients on a stable treatment regimen for sleep apnea for the last 3 months will be allowed to participate)
• Clinically significant abnormalities present on screening 12-lead electrocardiogram
• Women of childbearing potential using oral contraceptives who are not willing to use a second method of contraception during the study

Where it is running

• The Vermont Lung Center at the University of Vermont — Colchester, Vermont, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.